Search Results

Rectal cancer constitutes one-quarter of colorectal cancer cases and is the third most common gastrointestinal tract cancer, with approximately 40,000 cases diagnosed in the United States annually. 1 Although the survival of patients with rectal

Background Breast cancer is the second leading cause of cancer death for women in the United States, with an estimated 276,480 new diagnoses and 42,170 breast cancer–related deaths in 2020. 1 Despite mortality declining by 40% between 1989 and

In 2013, approximately 65,150 individuals in the United States were diagnosed with renal cell cancer (RCC). 1 Most (>60%) will have localized disease at diagnosis, although recurrences will develop in approximately 40% of patients initially

Dr. Glaspy has received research support from Amgen Inc., Ortho Biotech, L.P., and Roche. References 1. Bohlius J Wilson J Seidenfeld J . Erythropoietin or darbepoetin for patients with cancer . Cochrane Database Syst Rev

services in early-stage breast cancer (ESBC), stating, “Don't perform PET, CT, and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis.” 1 For these recommendations, the Choosing Wisely initiative defines early

Overview All cancers develop as a result of mutations in certain genes, such as those involved in the regulation of cell growth and/or DNA repair, 1 , 2 but not all of these mutations are inherited from a parent. For example, sporadic

Gastroesophageal cancers are a heterogeneous group of cancers that develop insidiously and carry poor prognoses. 1 , 2 Worldwide, gastric adenocarcinoma and esophageal cancer represent the fourth and sixth most common causes of cancer

For the treatment of gastric and esophageal cancers, recent studies have demonstrated robust findings for new drugs that, as a consequence, are becoming FDA-approved and added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

In 2012, more than 200,000 women in the United States were diagnosed with invasive breast cancer. Despite the high incidence, 5-year curative rates for early-stage cancer exceed 85%, reflecting remarkable progress over the past 3 decades in